{
    "nct_id": "NCT06884865",
    "official_title": "A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee",
    "inclusion_criteria": "* Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions.\n* Subjects must be male or female and 45 to 80 years old, inclusive, at Screening.\n* Subjects must exhibit symptoms associated with osteoarthritis of the index knee for ≥12 months before Screening (subject self-reporting is acceptable).\n* Subjects must have index knee pain for >15 days over the last month before Screening (subject self-reporting is acceptable).\n* Subjects must have failed 2 or more therapies: Restricted physical activity as per Osteoarthritis Research Society International (OARSI) core level recommendation, ie, \"structured land-based exercise\" (this may include physical therapy), and failure of an additional type of conservative therapy for OA of the index knee, eg, nonselective NSAIDs or COX-2 inhibitors, in the past 12 months.\n* Subjects must have a body mass index (BMI) ≤40 kg/m2 at Screening.\n* Subjects must have an index knee examination indicating the index knee and the intended injection site area are free of any signs of local or joint infection at Baseline.\n* Subjects must have an index knee Average Daily Knee Pain (NRS) between ≥5.0 and ≤9.0 at Screening and Baseline.\n* Sexually active subjects of child-bearing potential (SOCBP) and their partners must agree to use effective birth control while in the study\n* Subjects must have active synovitis in the index knee as determined by ultrasound Doppler.\n* Subjects must exhibit American College of Rheumatology Criteria (clinical and radiological) for osteoarthritis as follows:\n\n  1. Knee pain\n  2. At least 1 of the following:\n\n  i. Age >50 years ii. Morning stiffness <30 minutes iii. Crepitus on knee motion c. Osteophytes\n* Subjects must have K-L Grade 2, 3, or 4 in the index knee based on X-rays performed during Screening and confirmed by trained radiographers at a central facility before enrollment\n* Subjects need to show the presence of moderate or severe synovitis based on 11-point synovitis score using contrast-enhanced MRI\nHealthy volunteers allowed\nMust have minimum age of 45 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Subjects have any current or prior diagnosis of autoimmune connective tissue disorders, secondary OA conditions, benign synovial tumors, gout/pseudogout, reactive arthritis, RA, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.\n* Subjects have any active systemic or local infection, including infection of the index knee\n* Subjects are unable to undergo MRI with contrast MRI\n* Subjects with X-ray or MRI exclusionary events\n* Subjects have an unstable index knee joint (eg, torn anterior cruciate ligament) within 12 months of Screening\n* Subjects have used any approved or investigational IA drug/biologic in index knee within 6 months of Screening (eg, hyaluronic acid, platelet rich plasma, stem cells, prolotherapy, and amniotic fluid injection)\n* Subjects are receiving or have received any gene therapy treatment (eg, IL-1Ra) in the past 3 years\n* Subjects have used IA steroids ≤3 months before screening\n\nOther protocol-defined criteria apply",
    "miscellaneous_criteria": ""
}